BACKGROUND AND PURPOSE: Inflammation plays a critical role in the development of vascular disease, and increased levels of the inflammatory biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), and high-sensitivity C-reactive protein (hs-CRP) have been shown to be associated with an increased risk for ischemic stroke. METHODS: In a prospective case-cohort (n=949) study in 12 762 apparently healthy, middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, we first examined whether Lp-PLA(2) and hs-CRP levels improved the area under the receiver operator characteristic curve (AUC) for 5-year ischemic stroke risk. We then examined how Lp-PLA(2) and hs-CRP levels altered classification of individuals into low-, intermediate-, or high-risk categories compared with traditional risk factors. RESULTS: In a model using traditional risk factors alone, the AUC adjusted for optimism was 0.732, whereas adding hs-CRP improved the AUC to 0.743, and adding Lp-PLA(2) significantly improved the AUC to 0.752. Addition of hs-CRP and Lp-PLA(2) together in the model improved the AUC to 0.761, and the addition of the interaction between Lp-PLA(2) and hs-CRP further significantly improved the AUC to 0.774. With the use of traditional risk factors to assess 5-year risk for ischemic stroke, 86% of participants were categorized as low risk (<2%); 11%, intermediate risk (2% to 5%); and 3%, high risk (>5%). The addition of hs-CRP, Lp-PLA(2), and their interaction to the model reclassified 4%, 39%, and 34% of the low-, intermediate- and high-risk categories, respectively. CONCLUSIONS: Lp-PLA(2) and hs-CRP may be useful in individuals classified as intermediate risk for ischemic stroke by traditional risk factors.
BACKGROUND AND PURPOSE:Inflammation plays a critical role in the development of vascular disease, and increased levels of the inflammatory biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), and high-sensitivity C-reactive protein (hs-CRP) have been shown to be associated with an increased risk for ischemic stroke. METHODS: In a prospective case-cohort (n=949) study in 12 762 apparently healthy, middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, we first examined whether Lp-PLA(2) and hs-CRP levels improved the area under the receiver operator characteristic curve (AUC) for 5-year ischemic stroke risk. We then examined how Lp-PLA(2) and hs-CRP levels altered classification of individuals into low-, intermediate-, or high-risk categories compared with traditional risk factors. RESULTS: In a model using traditional risk factors alone, the AUC adjusted for optimism was 0.732, whereas adding hs-CRP improved the AUC to 0.743, and adding Lp-PLA(2) significantly improved the AUC to 0.752. Addition of hs-CRP and Lp-PLA(2) together in the model improved the AUC to 0.761, and the addition of the interaction between Lp-PLA(2) and hs-CRP further significantly improved the AUC to 0.774. With the use of traditional risk factors to assess 5-year risk for ischemic stroke, 86% of participants were categorized as low risk (<2%); 11%, intermediate risk (2% to 5%); and 3%, high risk (>5%). The addition of hs-CRP, Lp-PLA(2), and their interaction to the model reclassified 4%, 39%, and 34% of the low-, intermediate- and high-risk categories, respectively. CONCLUSIONS:Lp-PLA(2) and hs-CRP may be useful in individuals classified as intermediate risk for ischemic stroke by traditional risk factors.
Authors: E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema Journal: J Clin Epidemiol Date: 2001-08 Impact factor: 6.437
Authors: S M Grundy; R B D'Agostino; L Mosca; G L Burke; P W Wilson; D J Rader; J I Cleeman; E J Roccella; J A Cutler; L M Friedman Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: N S Rost; P A Wolf; C S Kase; M Kelly-Hayes; H Silbershatz; J M Massaro; R B D'Agostino; C Franzblau; P W Wilson Journal: Stroke Date: 2001-11 Impact factor: 7.914
Authors: J Montaner; P Chacón; J Krupinski; F Rubio; M Millán; C A Molina; P Hereu; M Quintana; J Alvarez-Sabín Journal: Eur J Neurol Date: 2007-12-07 Impact factor: 6.089
Authors: Kevin S Heffernan; Richard H Karas; Eshan A Patvardhan; Haseeb Jafri; Jeffrey T Kuvin Journal: Clin Cardiol Date: 2010-02 Impact factor: 2.882
Authors: Mae Thamer; James S Kaufman; Yi Zhang; Qian Zhang; Dennis J Cotter; Heejung Bang Journal: Am J Kidney Dis Date: 2015-06-26 Impact factor: 8.860
Authors: James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson Journal: Stroke Date: 2014-10-28 Impact factor: 7.914
Authors: Joao D Fontes; Jennifer F Yamamoto; Martin G Larson; Na Wang; Dhayana Dallmeier; Michiel Rienstra; Renate B Schnabel; Ramachandran S Vasan; John F Keaney; Emelia J Benjamin Journal: Atherosclerosis Date: 2013-02-04 Impact factor: 5.162
Authors: Kevin McGeechan; Gerald Liew; Petra Macaskill; Les Irwig; Ronald Klein; Barbara E K Klein; Jie Jin Wang; Paul Mitchell; Johannes R Vingerling; Paulus T V M de Jong; Jacqueline C M Witteman; Monique M B Breteler; Jonathan Shaw; Paul Zimmet; Tien Y Wong Journal: Am J Epidemiol Date: 2009-11-01 Impact factor: 4.897